Last reviewed · How we verify
Dexmedetomidine Hydrochloride (dexmedetomidine-hydrochloride)
Dexmedetomidine Hydrochloride is a relatively selective centrally acting alpha 2 -adrenergic agonist with sedative properties.
Dexmedetomidine Hydrochloride is a marketed drug by Pfizer Inc. It is a relatively selective centrally acting alpha 2 -adrenergic agonist with sedative properties. The key indications include sedation of non-intubated patients in the ICU or in a hospital setting receiving mechanical ventilation. Dexmedetomidine Hydrochloride has clinical differentiation due to its sedative properties and alpha 2 selectivity. The commercial significance is evident with revenue of 63.6B. There are 100 trials and 103 publications associated with the drug. Pipeline developments are not mentioned.
At a glance
| Generic name | dexmedetomidine-hydrochloride |
|---|---|
| Sponsor | Pfizer |
| Drug class | dexmedetomidine |
| Target | Alpha-1A adrenergic receptor |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 1999 |
Mechanism of action
Dexmedetomidine Hydrochloride is a medication used for sedation in various settings. It works by activating alpha 2-adrenergic receptors in the brain, which leads to sedative effects. This mechanism of action is unique compared to other sedatives, making it a valuable option for certain patients.
Approved indications
- Sedation of non-intubated patients in the intensive care unit (ICU) or in a hospital setting receiving mechanical ventilation.
- Sedation of mechanically ventilated adult patients in an intensive care unit or coronary care unit.
- Sedation of intubated and mechanically ventilated adult patients in an intensive care unit or coronary care unit.
Common side effects
- Hypotension
- Hypertension
- Nausea
- Bradycardia
- Atrial Fibrillation
- Pyrexia
- Dry Mouth
- Vomiting
- Hypovolemia
- Atelectasis
- Pleural Effusion
- Agitation
Drug interactions
- Anesthetics, Sedatives, Hypnotics, Opioids
- Anesthetics, Sedatives, Hypnotics, Opioids
- Isoflurane
- Propofol
- Alfentanil
- Midazolam
- Rocuronium
Key clinical trials
- Using Lidocaine or Dexmedetomidine to Help Control Blood Pressure Spikes From a Tourniquet During Knee Surgery (PHASE2)
- Dexmedetomidine Use in Infants Undergoing Cooling Due to Neonatal Encephalopathy (DICE Trial) (PHASE2)
- PENG Block With Dexmedetomidine in Older Adults (NA)
- Effect of Tegileridine on Postoperative Bowel Function Recovery in Abdominal Surgery (PHASE4)
- BXCL501 After Stress to Increase Recovery Success (PHASE2)
- Effect of Dexmedetomidine on Lung Protection in Elderly Patients Undergoing Laparoscopic Surgery for Colorectal Cancer (NA)
- Hypotensive Anesthesia for Orthognathic Surgery (PHASE4)
- Observation of the Effect of Preoperative Use of Dexmedetomidine Hydrochloride Nasal Spray on Optimizing Awake Sedation During Breast-Conserving Surgery for Breast Cancer and Postoperative Awake Status (PHASE3)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexmedetomidine Hydrochloride CI brief — competitive landscape report
- Dexmedetomidine Hydrochloride updates RSS · CI watch RSS
- Pfizer portfolio CI